BioTime Inc. (NYSE:BTX) touted today positive preclinical results for its HyStem hydrogel drug-delivery technology, demonstrating that targeted intracerebral delivery of brain-derived neurotrophic factor may alleviate the effects of ischemic brain injury and reduce neuroinflammation. The study, published in the International Journal of Molecular Sciences, focused on the effects of BDNF on sensorimotor function, infarct volume and neuroinflammation […]
Philips-Medisize launches third-gen Connected Health Platform
Phillips-Medisize said today it completed the roll-out of its third-gen Connected Health Platform, a cloud-based data system for pharmaceutical and drug delivery device developers. The newly launched system includes information sharing and analytics capabilities as well as cybersecurity precautions and streamlined regulatory documentation, the Hudson, Wisc.-based company said. The third-gen Connected Health Platform includes an […]
Researchers develop nanodevice to deliver immunotherapy
Researchers at Houston Methodist Research Institute have created a nanodevice that can be used to deliver immunotherapy to treat triple-negative breast cancer. The tiny device is designed to be inserted directly into a tumor, delivering a localized, sustained-release dose of therapy and eliminating the need for patients to undergo IV treatments. The scientists described their […]
FDA proposes global harmonization of standards for generic drug developers
The FDA has proposed that the International Council on Harmonisation set global standards for generic drug developers, according to a report from FDA chief Dr. Scott Gottlieb. The U.S. regulatory agency argued that companies making generic drugs should be able to implement a single global drug development program and file for approval across multiple markets […]
Novaliq touts topline data for dry eye disease drug
Novaliq today touted topline data from the first pivotal trial of its CyclASol 0.1% drug designed to treat dry eye disease. The company is hoping to position its 0.1% cyclosporine A product as advantageous compared to other ophthalmic treatments, noting that its EyeSol technology helps boost the drug’s efficacy and provide an earlier onset of […]
Report: Next-gen Amazon Alexa could detect illness, provide medicine suggestions
Future generations of Amazon‘s (NSDQ:AMZN) Alexa virtual assistant may be able to determine when its users are ill and provide medication recommendations, according to a new report from The Telegraph. The online retail giant has reportedly patented a new version of Alexa designed to analyze speech and identify signs of illness, according to the report. […]
Philips’ HealthSuite will track Ypsomed’s connected self-medication devices
Philips and Ypsomed said today that they will jointly develop a solution for Ypsomed’s new self-medication adherence monitoring services based on Philips’ HealthSuite digital platform. The combination of Ypsomed’s connected devices and Philips’ (NYSE:PHG) cloud-based digital platform will allow Ypsomed’s pharmaceutical customers to deliver value-added services aimed at improving patient outcomes, the companies said in […]
J&J inks collab deal to develop MERS vaccine
Healthcare giant Johnson & Johnson (NYSE:JNJ) today announced a new collaborative deal as it looks to develop a vaccine against Middle East Respiratory Syndrome Coronavirus. The collaborative deal is between J&J’s Janssen Vaccines & Prevention division, the Coalition for Epidemic Preparedness Innovations and The Jenner Institute at the University of Oxford, J&J said. Through the deal, Janssen […]
NIH kicks off study of combo antibody HIV therapy
The National Institutes of Health reported this week that it launched a clinical trial evaluating a combination of antibodies in people with HIV. The early-stage study is designed to assess whether periodic infusions of two HIV-specific antibodies are safe in people living with HIV. Researchers also plan to gather preliminary data assessing how effectively the […]
EyeGate’s Phase 3 EGP-437 study fails to show non-inferiority
Ophthalmalogical-focused developer EyeGate Pharma said this week that the Phase 3 study of its EGP-437 delivered through its EyeGate II drug delivery system did not show non-inferiority to the prednisolone acetate ophthalmic solution control group. The Phase 3 study was evaluating the safety and efficacy of the EGP-437 with the EyeGate II in patients with […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 42
- Next Page »
